InRetail Perú Corp (INREF) Fair Value & Analysis
Consumer Cyclical · US · Market cap $2.9B
Fair value as of: Jun 24, 2026
Analysis
InRetail Perú Corp (INREF) currently trades at $26.84, while our model-based Fair Value estimate is $46.25 — implying the stock looks roughly 72.3% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
InRetail Perú Corp., together with its subsidiaries, operates as a multi-format retailer primarily in Peru. It operates through five segments: Food Retail, Pharmacies, Distribution, Shopping Malls, and Digital, and Others. The company operates hypermarkets; pharmacies under the Inkafarma and Mifarma brand names; shopping centers under the Real Plaza brand; and supermarkets under the Plaza Vea Hiper, Plaza Vea Super, Vivanda, Makro, and Mass brand names. It also engages in development of real estate; distribution of pharmaceutical products; commercialization of cosmetic and pharmaceutical products, as well as food for medical use; leasing of space; and provision of digital services. InRetail Perú Corp. was incorporated in 2011 and is headquartered in Lima, Peru. InRetail Perú Corp. is a subsidiary of Intercorp Retail Inc.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is InRetail Perú Corp (INREF) undervalued?
What is the fair value of INREF?
What is the quality score of INREF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.